Skip to main content
. 2000 Apr 25;97(9):4760–4765. doi: 10.1073/pnas.97.9.4760

Figure 4.

Figure 4

Tetramer analysis of CD8+ T cells from two stage IV melanoma patients, NW29 and NW731, with NY-ESO-1-positive tumors and NY-ESO-1 antibody. Tests with unsensitized PBLs (Upper) and CD8+ T cells presensitized with NY-ESO-1 p157–165 (Lower) for each patient are shown. Samples were double-stained with phycoerythrin-labeled tetramers and anti-Tricolor-CD8 mAb. Tetramers were prepared with NY-ESO-1 p157–165, Melan-A p26–35, and MAGE-3 p271–279 as indicated at the bottom of each grid. Values indicate percentage of tetramer-positive CD8+ T cells.